Journal of Tropical Pediatrics Advance Access originally published online on November 29, 2007
Journal of Tropical Pediatrics 2008 54(3):196-199; doi:10.1093/tropej/fmm101
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brief Reports |
Intravenous Magnesium Sulphate vs. Inhaled Nitric Oxide for Moderate, Persistent Pulmonary Hypertension of the Newborn. A Multicentre, Retrospective Study
aDivision of Neonatology, Department of Pediatrics, Università Federico II, Naples, Italy
bNeonatal Intensive Care Unit, Ospedale di Caserta
cNeonatal Intensive Care Unit, Ospedale di Crotone
dNeonatal Intensive Care Unit, Ospedale Monaldi
eNeonatal Intensive Care Unit, Ospedale Evangelico Villa Betania
fNeonatal Intensive Care Unit, Ospedale Fatebenefratelli, Italy
Correspondence: Francesco Raimondi, MD, Division of Neonatology, Department of Pediatrics, Università Federico II, Naples, Italy. Tel: +39-0817462885. Fax: +39-0817463268. E-mail <raimondi{at}unina.it>.
| Abstract |
|---|
We have compared intravenous magnesium sulphate vs. inhaled nitric oxide in the therapy of moderate persistent pulmonary hypertension of the neonate. A retrospective collection of clinical data from 58 neonates was carried out in six neonatal intensive care units of Southern Italy sharing the same operational protocols. In our setting, both drugs were effective in treating moderate persistent pulmonary hypertension of the neonate but nitric oxide (NO) treatment resulted in much faster amelioration of oxygenation index, taken as a marker of the underlying condition. No significant difference was recorded in immediate or long-term complications. We conclude that, wherever NO facilities are not readily available, magnesium sulphate is a safe and cheaper alternative for first-line treatment of moderate persistent pulmonary hypertension of the neonate.
Key Words: magnesium sulphate neonate nitric oxide